Berger, J. S., & Hacke, W. (2011). Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American heart journal, 162(1), .
Chicago-Zitierstil (17. Ausg.)Berger, Jeffrey S., und Werner Hacke. "Bleeding, Mortality, and Antiplatelet Therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial." American Heart Journal 162, no. 1 (2011).
MLA-Zitierstil (9. Ausg.)Berger, Jeffrey S., und Werner Hacke. "Bleeding, Mortality, and Antiplatelet Therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial." American Heart Journal, vol. 162, no. 1, 2011.